Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Lung cancer DNA plasmid vaccine and preparation method thereof

A plasmid and vaccine technology, applied in the field of DNA vaccines, can solve the problems of insufficient cancer specificity, damage to normal tissues and organs, etc., and achieve the effects of safe and reliable cost, inhibition of development and metastasis, and good therapeutic effect

Inactive Publication Date: 2009-02-11
NINGBO UNIV
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the three conventional treatments for cancer are surgery, chemotherapy and radiotherapy, which are not specific enough to treat cancer and often cause damage to normal tissues and organs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lung cancer DNA plasmid vaccine and preparation method thereof
  • Lung cancer DNA plasmid vaccine and preparation method thereof
  • Lung cancer DNA plasmid vaccine and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Construction and purification of lung cancer DNA plasmid vaccine: According to the epitopes EVDPIGHLY and FLWGPRALY of lung cancer antigen MAGE-3 recognized by specific CTL and the epitopes SLLMWITQC and QLSLLMWIT of NY-ESO-1, a fusion gene containing the above four epitopes was designed and synthesized , and connect each epitope with flexible tetrapeptide (GPGP) (the size is about 144bp, see the results image 3 ), and subcloned it into the CMV promoter of the pNGVL4a plasmid to obtain the pNGVL-MAGE-NY-ESO plasmid, and inserted the GM-CSF gene fragment of about 432bp obtained by reverse transcription PCR into another part of the above plasmid Under a CMV promoter, constructs such as figure 1 The pNGVL-GM-CSF-MAGE-NY-ESO plasmid shown in the structure; the GM-CSF gene fragment is obtained by conventional methods: first, isolate human peripheral blood leukocytes, extract total RNA, and then design according to the known sequence (Genebank no.AAA52578) Primers, obtained...

Embodiment 2

[0027]Lung cancer DNA plasmid vaccine injection and expression analysis in mammalian cells thereof: the high-purity lung cancer DNA plasmid vaccine pNGVL-GM-CSF-MAGE-NY-ESO obtained in Example 1 and cationic liposome DOSPER (purchased from Roche company ), the mass ratio of DNA plasmid vaccine and cationic liposome is 10:1 and dissolved in phosphate buffer solution to prepare DNA plasmid vaccine injection, and the highly purified plasmid in DNA plasmid vaccine injection is wrapped by cationic liposome .

[0028] Transfect the DNA plasmid vaccine injection into mammalian cos-7 cells, and continue culturing in DMEM medium containing 10% fetal bovine serum at 37 degrees. After harvesting the cultured cells at different periods of time, use flow cytometry (BD company) to analyze the expression of GM-CSF and the cytokines such as IL-4, IL-6 and IFN-γ stimulated by GM-CSF, and confirm that the plasmid stimulates the immune response Ability. The calculation results showed that the ...

Embodiment 3

[0030] Establishment of lung cancer model mice: According to literature reports, BALB / c mouse lung cancer was induced by diethylnitrosamine (DEN): mice were subcutaneously injected with 1% DEN aqueous solution once a week, each dose was 56mg / kg, and the total dose of DEN reached 1176mg , when the observation time is about half a year, the incidence rate of lung cancer is identified by immunohistochemistry, and the general incidence rate can reach 94%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a lung cancer DNA plasmid vaccine which comprises a plasmid vector containing a fusion gene MAGE-NY-ESO of four epitopes of lung cancer antigens MAGE-3 and NY-ESO-1. The fusion gene MAGE-NY-ESO has a nucleotide sequence shown as SEQ ID NO.1; the invention also discloses a preparation method of the DNA plasmid vaccine, wherein, a DNA plasmid containing a coding sequence of a target antigen is used as a new generation of therapeutic vaccines. The vaccine induces and generates an immunoreaction with specificity aiming at the relevant coding antigen in the body and effectively restrains the development and transfer of lung cancer. Therefore, the vaccine is the DNA plasmid vaccine with simple preparation, low cost, safety and reliability as well as the effective treatment of lung cancer.

Description

technical field [0001] The invention relates to a DNA vaccine, in particular to a lung cancer DNA plasmid vaccine and a preparation method thereof. Background technique [0002] Lung cancer is currently one of the most common malignant tumors in the world. In recent decades, the incidence and mortality of lung cancer have increased significantly, and the upward trend ranks first among various malignant tumors. The therapeutic effect of lung cancer has not improved significantly in the past ten years. The main reason is that the biological characteristics of lung cancer are very complex, the degree of malignancy is high, and most patients are already in the advanced stage when they are diagnosed. The ideal method of cancer treatment should be able to specifically remove cancerous tissue without destroying normal tissue. At present, the three conventional treatments for cancer are surgery, chemotherapy and radiotherapy, which are not specific enough to treat cancer and often ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K48/00A61P35/00A61P11/00
Inventor 龚朝辉乐燕萍龙香娥
Owner NINGBO UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com